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Abstract 
Congenital myasthenic syndromes (CMS) are a rare heterogeneous group of inherited neuromuscular 
disorders associated with distinctive clinical, electrophysiological, ultrastructural and genetic abnormalities. 
These genetic defects either impair neuromuscular transmission directly or result in secondary impairments, 
which eventually compromise the safety margin of neuromuscular transmission.  In this report we will explore 
the significant progress made in understanding the molecular pathogenesis of CMS, which is important for 
both patients and clinicians in terms of reaching a definite diagnosis and selecting the most appropriate 
treatment. 
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Introduction 
The neuromuscular junction is a specialized synapse with a complex molecular architecture, which serves to 
achieve reliable transmission between the nerve terminal and muscle fibre.  It is composed of three main 
compartments: the presynaptic part formed by the nerve terminal is responsible for acetylcholine synthesis, 
storage and release.  The synaptic cleft contains the basal lamina, which constitutes a sound extracellular 
matrix, both structurally and functionally. This maintains good adhesion between the synaptic membranes and 
facilitates neuromuscular communication.  The postsynaptic muscle membrane, also called endplate has a 
multitude of folds, which contains several acetylcholine receptor clusters on its surface.
1
    
Depolarisation at the nerve terminal opens the presynaptic voltage-gated calcium (Ca
++
) channels allowing 
influx of Ca
++
 into the presynaptic nerve bud, which triggers release of multiple vesicles (quanta) of 
acetylcholine by exocytosis.  Acetylcholine diffuses across the synaptic space and binds to the acetylcholine 
receptors.  This in turn results in influx of cations, mainly sodium (Na+) but also Ca
++
 that induces 
depolarisation of the muscle endplate generating endplate potentials (EPP) and ultimately muscle contraction.  
An important concept in neuromuscular junction functional integrity is the safety margin, which reflects the 
extent of interference of the synaptic mechanisms that can exist without failure of transmission.
2-3
 
Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited neuromuscular disorders in 
which the safety margin of neuromuscular transmission is compromised. 
4-5
 To date 13 genes have been found 
to cause CMS when mutated.  These are the pre-synaptic acetyltransferase CHAT 
6
, the gene COLQ
7-8-9
 
encoding the triple stranded collagenic tail of the synaptic acetylcholinesterase (AChE), the genes encoding the 
different subunits of the postsynaptic acetylcholine receptors (AChR) CHRNA1, CHRNB1, CHRND, CHRNE and 
CHRNG, the RAPSN gene encoding the postsynaptic protein rapsyn
10
, the postsynaptic muscle specific kinase 
(MUSK) gene
11
, the postsynaptic sodium channel (SCN4)
12
, the DOK7 gene encoding the postsynaptic Dok-7 
protein
13-14
, the LAMB2 encoding the synaptic Laminin B2 protein
15
, the AGRN gene encoding the postsynaptic 
agrin protein
16
 and the PLEC1 gene encoding the postsynaptic protein plectin.
17-18-19
 
Genetic classification of the different CMS cohorts reveals that the majority of CMS patients have mutations in 
genes expressing postsynaptic endplate proteins
4-20 
(table 1). Despite tremendous progress in identifying the 
molecular basis of the different CMS subtypes, almost half of the CMS population remains genetically 
undiagnosed.  For instance, limb girdle CMS with tubular aggregates remains a fascinating but as yet 
genetically uncharacterized group of patients waiting to be unravelled.
21
 Furthermore, there is significant 
variability in clinical phenotype, onset and course of disease and response to therapy in patients sharing the 
same genetic defect.  In spite of this, treatment efficacy and safety seem closely linked to the underlying 
molecular aetiology. 
In this report we will classify CMS based on the site of molecular defect in the neuromuscular junction.  We will 
focus on recent progress in understanding the pathomechanisms underlying the different CMS categories and 
highlight any relevant clinical features that can guide clinicians in making the correct diagnosis and selecting 
the most efficacious and least harmful treatment. 
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Presynaptic CMS 
Choline acetyltransferase (ChAT) Deficiency  
A decrease in ChAT activity has been associated with a number of developmental and neurodegenerative 
disorders, including Alzheimer’s disease, Huntington disease, amyotrophic lateral sclerosis, Schizophrenia, Rett 
syndrome and Sudden Infant Death Syndrome (SIDS).
22
  However, the most striking association of ChAT 
deficiency causing disease is seen in CMS with episodic apnoea (CMS-EA)
6
. 
The CHAT gene encodes the choline acetyltransferase protein, which is located at the pre-synaptic nerve 
terminal and is responsible for acetylcholine synthesis from acetyl coenzyme A and choline
6
.   Mutations in this 
gene have been shown to be associated with a reduction in ChAT synthesis or impairment in ChAT catalytic 
function.
3
  Analysis of the crystal structure of ChAT rat protein reveals that CHAT mutations are located either 
at the substrate binding site where the enzyme catalytic site is found or alternatively these mutations alter the 
function of the enzyme allosterically or by changing the folding or stability of the enzyme.
23-24
 The mutations 
identified to date have been scattered throughout the gene with no suggestion of “hotspots”. 
The CMS clinical phenotype in ChAT deficiency is associated with sudden and recurrent episodes of apnoea 
and bulbar weakness precipitated by infection, fever, excitement or no identifiable trigger against a 
background of variable fatigable weakness.
6
  The course of disease seems to follow two distinct trends with 
either neonatal onset respiratory distress with progressive improvement over time but then further 
respiratory relapses in adulthood or late onset (during infancy or childhood) respiratory crises with a more 
unpredictable course of disease.
25-26
 
Treatment is with AChE inhibitor therapy in variable doses with or without addition of 3, 4-diaminopyridine (3, 
4 DAP)
 27
.  There is some recent anecdotal evidence that midazolam may mitigate the severity of apnoeic 
episodes but further study is needed.
28
 
 
Synaptic CMS 
Acetylcholinesterase deficiency (AChE)  
The synaptic basal lamina associated CMS is caused by the absence of the asymmetric form of 
acetylcholinesterase (AChE) from the synaptic space.
7-8
 One, two or three globular subunits form the main 
structure of this synaptic enzyme, which needs to be anchored to the basal lamina for its proper function.  The 
ColQ protein is responsible for attaching acetylcholinesterase to the basal lamina. It is worth noting that 
endplate AChE deficiency is not caused by mutations in the ACHE gene but by recessive mutations in the COLQ 
gene encoding the collagenic tail subunit.  
ColQ is composed of an N-terminal proline-rich region attachment domain (PRAD), a collagenic central domain 
and a C-terminal region enriched in charged residues and cysteines.  Two heparan sulphate proteoglycan 
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binding domains in the collagen domain and the C-terminal domain anchor AChE in the synaptic space. 
29-30-31
 
No fewer than 30 mutations have been reported so far, most of which are frameshift and nonsense mutations 
that truncate the ColQ protein distal to the PRAD domain.
4-32
   
Absence of AChE results in excess ACh in the synaptic cleft causing abnormal activation of the AChR and 
prolonged duration of the synaptic current.  This in turn evokes repetitive compound action potentials, also 
seen in slow channel syndromes, and instigates an endplate myopathy through cation overload. 
The course of disease in ColQ deficient patients can either be associated with a progressive trend leading to 
significant disability or alternatively can present with a later onset of disease with a much milder progression 
over the years.  Despite the clear clinical heterogeneity, a number of distinguishing features have been 
observed in this subgroup including the onset of symptoms in the neonatal period, evidence of delayed motor 
milestones, frequent early respiratory complications, sometimes needing ventilator support, and ocular 
involvement with evidence of ptosis, ophthalmoparesis and sometimes abnormally slow pupillary reactions.
9
 
The neurophysiological findings are invariably abnormal and can be diagnostically helpful when repetitive 
CMAPs are evoked. Treatment with choline esterase inhibitors has been shown to be inefficacious or even 
dangerous in this CMS subgroup.  In contrast, ephedrine seems to lead to clinical improvement with fewer 
tendencies to respiratory complications.
27
 
 
Laminin B2 deficiency 
Laminins are glycoproteins found in the basal lamina composed of an alpha, beta and gamma subunits. The 
beta2 chain encoded by the LAMB2 gene is found in all the laminin heterotrimers located at the 
neuromuscular junction and seems to play an important role in synaptogenesis.
33
 Mutations in the laminin β2 
subunit have previously been described in relation to Pierson syndrome typically associated with severe renal 
and ocular defects leading to death within weeks or months. 
There is one case report in the literature describing a female adult patient presenting with renal impairment in 
early childhood needing kidney transplantation.  She also had delayed motor milestones, ptosis, 
ophthalmoparesis, abnormal pupils and macular abnormalities.   Neurophysiological studies confirmed a 
neuromuscular transmission defect.  Treatment with cholinesterase inhibitors led to worsening neuromuscular 
weakness.  Ephedrine was more beneficial.  Two novel recessive truncating mutations in the LAMB2 gene were 
confirmed.
15
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Postsynaptic CMS 
This is by far the commonest group of CMS.  It is caused by the interruption of an important pathway involving 
several postsynaptic proteins including agrin, muscle specific tyrosine kinase (MuSK), downstream of kinase 
(Dok-7), acetylcholine receptors (AChRs) and the AChR-clustering protein rapsyn.  This pathway is believed to 
be responsible for the stability of the synaptic architecture and for the aggregation and positioning of AChR on 
the post-synaptic membrane.
34
 Thus postsynaptic CMS related to AChR deficiency are not only caused by 
mutations in the different subunits of AChR but also includes other postsynaptic proteins. 
 
Defects in acetylcholine receptor subunits 
Molecular defects involving the postsynaptic AChR lead to either deficiency of the receptor with or without 
kinetic defects or cause kinetic abnormalities with or without minor AChR deficiency.  The kinetic mutations 
fall into two categories according to whether they induce slow or fast channel syndromes 
4-20
. 
 
Primary AChR deficiency 
This is associated with a recessively inherited form of CMS, most commonly associated with mutations in the 
epsilon subunit. This predilection is probably related to the presence of the gamma foetal isoform, which can 
partially compensate for the absence of epsilon subunit.  Moreover, the gene encoding the epsilon subunit 
contains multiple GC repeats that are likely to predispose to DNA rearrangement. 
4-20
 A multitude of private 
mutations have been identified in this subgroup although a few founder mutations are recognised in certain 
geographical or ethnical distributions such as the North African, Spanish/Portuguese and Gypsy populations 
(table2). 
Clinically, ptosis with ophthalmoparesis and global weakness are invariably found in this CMS group.  The 
course of disease is fairly static, although transient exacerbation can be triggered by infection. The spectrum of 
clinical severity varies greatly and both intrafamilial and interfamilial differences are seen.
4-5-20
 
 
Kinetic defects in AChR 
Fast channel syndromes 
Fast channel mutations cause “loss of function” of the AChR leading to reduced affinity for ACh, and 
abnormally brief channel opening events. This is a relatively rare form of CMS associated with mostly recessive 
mutations in the AChR α, δ and ε subunits.
24
 Great clinical variability is observed but patients often present at 
birth with respiratory and/or bulbar problems which can be associated with increased mortality in the 
neonatal period.  Ocular symptoms are invariably present.   A partial response to anticholinesterases and 3,4-
DAP has been noted.  
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Slow channel CMS 
This category of CMS arises from “gain of function” mutations, which are typically dominant in inheritance and 
can involve any of the AChR subunits.
4
 These mutations cause sustained activation of the AChR either by 
enhancing its affinity for ACh or delaying channel closure.  
The prolonged AChR channel activation outlasts the refractory period of the muscle fibre action potential so 
that a single nerve stimulus evokes repetitive compound action potentials.  Moreover, this abnormal channel 
opening causes postsynaptic cation overload that leads to an endplate myopathy. 
Clinically, this form of CMS usually presents in childhood with evidence of delayed motor milestones and 
ophthalmoparesis with ptosis.  The neck muscles and the long finger and wrist extensors seem to be 
preferentially weaker. Conventional treatment with anticholinesterases or 3,4-DAP can worsen symptoms.  
Long acting open channel blockers such as fluoxetine, quinidine, and ephedrine have been shown to be 
beneficial
27
. 
 
Escobar syndrome 
The AChR has 5 subunits, 2α, 1β, 1δ and 1 ε or γ subunits.  By substituting the γ to ε subunits in late foetal life, 
foetal receptors are gradually replaced by adult receptors.  The foetal AChR seems to play a pivotal role in 
neuromuscular organogenesis by acting as a guide for the primary encounter of axon and muscle in utero.
35-36
  
Escobar syndrome is an antenatal congenital myasthenic disorder in which neuromuscular organogenesis is 
flawed due to mutation in the γ subunit, encoded by CHRNG gene.  Although clinically variable, this syndrome 
typically presents with arthrogryposis multiplex congenital with joint contractures, pterygia, cryptochism in 
males and respiratory distress.  Because γ subunit expression does not extend beyond 33 weeks of gestation, 
patients with this molecular defect have no typical myasthenic symptoms after birth.
35
 There is some 
suggestion that certain homozygous mutations in the γ subunit result in recurrent miscarriages.  In the right 
context, this may well be worth exploring when counselling affected families. 
It worth mentioning that mutations in the other subunits of the AChR (CHRNA1, CHRNB1, CHRND) as well as 
RAPSN and DOK7 genes have also been linked to in utero defects such as foetal akinesia syndrome.
37-38
   
 
Rapsyn deficiency 
This is another important cause of CMS.  Rapsyn is a postsynaptic protein that comprises several functional 
domains: a myristoylated N-terminal is required for membrane interaction.
39
: 7 tetratricopeptide repeats (TPR) 
are important for rapsyn self-aggregation
40
 and binding to the cytoplasmic portion of the specific muscle 
kinase Musk
41
; the coiled coil domain interacts with the cytoplasmic loops of AChR subunits
42
; and the C 
terminal domain binds to β dystroglycan and thereby links the rapsyn-AChR complex to the cytoskeleton
43
. 
Recessive mutations in the RAPSN gene are a relatively common cause of CMS and result in postsynaptic AChR 
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deficiency.  Until recently, most patients harbouring mutations in RAPSN were either homozygous or 
heterozygous for the N88K mutation in exon 2
44-45
.  In a recent French CMS series of 20 patients with 
confirmed causative RAPSN mutations, three patients had the N88K substitution but the sequencing failed to 
depict a second pathogenic mutation.  Using qPCR analysis, three chromosomal microdeletions were found.  
All these multi-exon deletions corresponded to the missing pathogenic allelic mutation
46.
  Of note, a similar 
finding was reported by Müller et al in one patient with a chromosomal microdeletion event in the RAPSN 
gene.
47
  
The clinical phenotype of rapsyn-CMS varies from severe hypotonia, arthrogryposis, dysmorphism and the 
presence of a high arched palate at birth to mild limb muscle weakness.  Early and late onset phenotypes have 
been described.  Recurrent apnoeic episodes and absence of ocular features have been suggested as possible 
discerning features between rapsyn-CMS and low expressor mutations in the AChR ε subunit.
48
 This form of 
CMS improves during childhood with respiratory crises disappearing and weakness improving over time. 
Furthermore, patients often respond dramatically to anticholinesterase medication. Thus recognition of this 
CMS genotype early can prevent death in a condition with a good long-term outcome. 
 
MuSK deficiency 
During NMJ development, Musk plays a key role in the organisation of the postsynaptic actin cytoskeleton and 
AChR clustering through recruitment of several downstream kinases and phosphorylation of the AChR β 
subunit.
49-50
 Three different kinships have been described so far in association with Musk deficiency.
11-51-52
  
Despite significant variability in clinical phenotype and disease severity, most patients had ocular symptoms 
and fatigable limb weakness.  Respiratory complications were also noted either in the neonatal period or later 
in adulthood.  Cholinesterase inhibitors and 3, 4 DAP were of some limited benefit. 
 
Dok-7 deficiency 
In 2006, Okada et al functionally characterised Dok-7 and showed that it could induce aneural activation of 
MuSK and subsequent clustering of AChRs.  During the same year, Beeson et al identified DOK7 mutations in 
21 patients with a clinical diagnosis of CMS exhibiting a limb girdle phenotype.
13-14
 Since then DOK7 mutations 
have been confirmed in a significant number of other series. 
53-54-55-56-57
 The pathophysiological repercussions 
of DOK7 mutations appear to arise from abnormal activation of MuSK signalling leading to an abnormally 
unstable and simplified neuromuscular junction affecting both pre and postsynaptic structures.
14-55-58
 More 
recent animal studies using a zebrafish model suggest that Dok-7 deficiency may also impair slow muscle 
organisation, independent of Musk.
59
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The clinical phenotype is typically associated with normal initial motor milestones with weakness manifesting 
either in childhood or adulthood with predominant limb-girdle involvement, often sparing the extra-ocular 
muscles.  Occasionally, congenital stridor with idiopathic bilateral cord palsy can be the presenting symptoms 
in this form of CMS.
60
 Patient can report prolonged periods of worsening weakness and fatigue.  There is also 
anecdotal evidence of exacerbation of weakness in the context of pregnancy.   
Dok-7 CMS is associated with poor response and potentially worsening weakness with cholinesterase 
inhibitors and a rather erratic response to 3, 4 DAP.  However, there is reasonable evidence that ephedrine 
provides benefit.
56-62
 
 
Agrin deficiency  
Although agrin’s site of action is at the postsynaptic level, this protein is released by the presynaptic nerve 
terminal.  Agrin is a heparan sulphate proteoglycan that binds to low-density lipoprotein receptor–related 
protein 4 (LRP4) expressed in muscle, leading to activation of MuSK and subsequent clustering of essential 
postsynaptic proteins.
16
 
Agrin associated CMS has been described in only 2 adult patients with a fairly mild phenotype and no 
suggestion of progression.  Delayed motor milestones, ptosis with no ophthalmoparesis, mild to minimal 
proximal limb weakness were reported.  The patients had no bulbar or respiratory difficulties.  Repetitive 
CMAPS were evoked on EMG.  Treatment with cholinesterase inhibitors and 3, 4 DAP was ineffective but 
ephedrine was beneficial. 
 
Defects in the postsynaptic sodium channel (Nav1.4) 
There is one report of an adult female presenting with a congenital myasthenic syndrome associated with 
recurrent apnoeic crises, needing ventilatory support and learning difficulties.  The latter were attributed to 
anoxic brain damage. Neurophysiology was consistent with a myasthenic syndrome and pointed to the Na 
channel as a potential candidate gene.  Two mutations were identified one of which was felt to be pathogenic.  
The inheritance pattern remains unclear.
12
 
 
Plectin deficiency 
This is another very rare and emerging cause of CMS with only 3 case reports found in the literature.
17-18-19
 The 
PLEC1 gene encodes for plectin, a cytoskeleton linker protein widely distributed in muscle and epithelial 
tissues.
62
 Mutations in this gene have classically been associated with a skin disorder (epidermolysis bullosa 
simplex) with and without associated features such as cardiomyopathy, respiratory failure, oesophageal 
10 
 
atresia and late onset muscular dystrophy.  All reported patients had myasthenic symptoms from early infancy 
and subsequently developed mild to severe skin blistering in keeping with epidermolysis bullosa.  Treatment 
with 3, 4 DAP may be of some benefit in this subgroup. 
Summary 
Although a large number of CMS genes have been discovered, most patients have harboured mutations in 
AChR subunits especially the ε subunit, RAPSN, COLQ, CHAT and DOK7 genes.  Being aware of common 
founder mutations in certain populations can expedite the process of making the correct genetic diagnosis and 
providing safe and efficacious treatment. As in many neuromuscular disorders, a particular focus on 
respiratory and bulbar functions is essential in preventing serious and potentially fatal complications in a highly 
treatable condition like CMS. 
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Table 1: Estimated frequency of CMS subtypes based on individuals with CMS investigated at the 
Munich laboratory 
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Table 2: Genetic heterogeneity and treatment options in CMS depending on the underlying 
molecular defect 
 
